

Stephane Gibaud

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8901508/stephane-gibaud-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

33
papers

623
citations

14
h-index

24
g-index

37
ext. papers

691
ext. citations

4.5
avg, IF

3.38
L-index

#	Paper	IF	Citations
33	Anticancer properties of lipid and poly(ϵ -caprolactone) nanocapsules loaded with ferrocenyl-tamoxifen derivatives. <i>Journal of Pharmacy and Pharmacology</i> , 2018, 70, 1474-1484	4.8	5
32	Spray-dried microparticles of glutathione and S-nitrosoglutathione based on Eudragit FS 30D polymer. <i>Annales Pharmaceutiques Francaises</i> , 2017, 75, 95-104	1.3	8
31	The effect of intravenous isosorbide dinitrate in acute decompensated heart failure in hospital. <i>International Journal of Clinical Pharmacy</i> , 2017, 39, 536-541	2.3	1
30	Thiomers and their potential applications in drug delivery. <i>Expert Opinion on Drug Delivery</i> , 2017, 14, 601-610	8	16
29	Synthesis of S-nitrosoglutathione-alginate for prolonged delivery of nitric oxide in intestines. <i>Drug Delivery</i> , 2016, 23, 2927-2935	7	13
28	Phthalimido-ferrocidiphenol cyclodextrin complexes: Characterization and anticancer activity. <i>International Journal of Pharmaceutics</i> , 2015, 491, 323-34	6.5	10
27	Synthesis and characterization of S-nitrosoglutathione-oligosaccharide-chitosan as a nitric oxide donor. <i>Expert Opinion on Drug Delivery</i> , 2015, 12, 1209-23	8	6
26	Continuous infusion of piperacillin/tazobactam in patients with severe infections: A possible pharmacokinetic optimisation?. <i>Annales Pharmaceutiques Francaises</i> , 2014, 72, 146-51	1.3	
25	Effect of intravenous hydration in patients receiving bisphosphonate therapy. <i>International Journal of Clinical Pharmacy</i> , 2014, 36, 1277-81	2.3	1
24	Characterization of mitotane (α,β -DDD)-cyclodextrin inclusion complexes: phase-solubility method and NMR. <i>Annales Pharmaceutiques Francaises</i> , 2013, 71, 186-92	1.3	5
23	The antitumor effects of an arsthinol-cyclodextrin complex in a heterotopic mouse model of glioma. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2013, 85, 560-8	5.7	4
22	Microemulsions for oral administration and their therapeutic applications. <i>Expert Opinion on Drug Delivery</i> , 2012, 9, 937-51	8	42
21	Place du mitotane dans la prise en charge du carcinome corticosurrhalien. <i>Actualites Pharmaceutiques Hospitalieres</i> , 2011, 7, 39-41		1
20	Melarsoprol cyclodextrin inclusion complexes as promising oral candidates for the treatment of human African trypanosomiasis. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1308	4.8	41
19	Arsenic-Based Drugs: From Fowler's Solution to Modern Anticancer Chemotherapy. <i>Topics in Organometallic Chemistry</i> , 2010, 1-20	0.6	31
18	Arsthinol nanosuspensions: pharmacokinetics and anti-leukaemic activity on NB4 promyelocytic leukaemia cells. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 61, 1295-1301	4.8	5
17	Development of microemulsion of mitotane for improvement of oral bioavailability. <i>Drug Development and Industrial Pharmacy</i> , 2010, 36, 421-7	3.6	34

LIST OF PUBLICATIONS

16	Speciation of arsenic in urine following intravenous administration of arsthinol in mice. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2010 , 35, 59-65	2.7	2
15	Arsthinol nanosuspensions: pharmacokinetics and anti-leukaemic activity on NB4 promyelocytic leukaemia cells. <i>Journal of Pharmacy and Pharmacology</i> , 2009 , 61, 1295-301	4.8	2
14	Comparison of nanosuspensions and hydroxypropyl-beta-cyclodextrin complex of melarsoprol: pharmacokinetics and tissue distribution in mice. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2008 , 70, 649-56	5.7	40
13	Pharmacokinetics and tissue distribution of the antileukaemic organoarsenicals arsthinol and melarsoprol in mice. <i>Journal of Organometallic Chemistry</i> , 2007 , 692, 1348-1352	2.3	5
12	Cyclodextrin inclusion complexes of the central analgesic drug nefopam. <i>Drug Development and Industrial Pharmacy</i> , 2006 , 32, 1123-34	3.6	14
11	(2-Phenyl-[1,3,2]dithiarsolan-4-yl)-methanol derivatives show in vitro antileukemic activity. <i>Journal of Organometallic Chemistry</i> , 2006 , 691, 1081-1084	2.3	13
10	Melarsoprol-cyclodextrins inclusion complexes. <i>International Journal of Pharmaceutics</i> , 2005 , 306, 107-216.5	54	
9	Poly(epsilon-caprolactone) and Eudragit microparticles containing fludrocortisone acetate. <i>International Journal of Pharmaceutics</i> , 2004 , 269, 491-508	6.5	26
8	Slow-release melarsoprol microparticles. <i>International Journal of Pharmaceutics</i> , 2002 , 243, 161-6	6.5	16
7	Preparation of 3,4-diaminopyridine microparticles by solvent-evaporation methods. <i>International Journal of Pharmaceutics</i> , 2002 , 242, 197-201	6.5	6
6	Polyalkylcyanoacrylate nanoparticles as carriers for granulocyte-colony stimulating factor (G-CSF). <i>Journal of Controlled Release</i> , 1998 , 52, 131-9	11.7	51
5	Polyisobutylcyanoacrylate nanoparticles as drug carriers: influence of sulfur dioxide on the physico-chemical characteristics of ciprofloxacin- and doxorubicin-loaded nanoparticles. <i>International Journal of Pharmaceutics</i> , 1998 , 166, 117-120	6.5	9
4	Splenic trapping of nanoparticles: complementary approaches for in situ studies. <i>Pharmaceutical Research</i> , 1997 , 14, 463-8	4.5	39
3	Cells involved in the capture of nanoparticles in hematopoietic organs. <i>Journal of Pharmaceutical Sciences</i> , 1996 , 85, 944-50	3.9	44
2	Increased bone marrow toxicity of doxorubicin bound to nanoparticles. <i>European Journal of Cancer</i> , 1994 , 30A, 820-6	7.5	68
1	Detection of bacterial adenosine triphosphate through bioluminescence, applied to a rapid sterility test of injectable preparations. <i>Analytica Chimica Acta</i> , 1991 , 255, 423-425	6.6	1